Cognitive executive functioning in relation to HIV medication adherence among gay, bisexual, and other men who have sex with men

AIDS and Behavior

Volumn 12, Issue 1, 2008, Pages 68-77

  Solomon, Todd M ^a,b   Halkitis, Perry N ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Age; ART; Bisexual; Executive functioning; Gay; HIV; MSM; Treatment adherence

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; AGED; ARTICLE; BISEXUALITY; COGNITION; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PSYCHOLOGIC TEST;

ADULT; AGE FACTORS; AGED; ANTI-HIV AGENTS; BISEXUALITY; COGNITION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PATIENT COMPLIANCE;

EID: 38449110749     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-007-9273-0     Document Type: Article

References (61)

1. Albert, S. M., Todak, G., Elkin, E., Marder, K., Dooneief, G., & Stern Y. (1994). Time allocation and disability in HIV infection: A correlational study. Journal of Occupational Science, 1, 21-30.
2. Albert, S. M., Marder, K., Dooneief, G., Bell, K., Sano, M., & Todak, G. et al. (1995). Neuropsychologic impairment in early HIV infection. A risk factor for work disability. Archives of Neurology, 52(5), 525-530.
3. Ammassari, A., Antinori, A., Aloisi, M. S., Trotta, M. P., Murri, R., & Bartoli, L. et al. (2004). Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics, 45(5), 394-402.
4. Ammassari, A. A., Starace, F., Aloisi, M. S., Trotta, M. P., Murri, R., & D'Arminio Monforte, A. et al. (2003). Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity. Neurology, 61(5), 723-4; author reply 724.
5. Arbuthnott, K., & Frank, J. (2000). Trail making test, part B as a measure of executive control: Validation using a set-switching paradigm. Journal of Clinical and Experimental Neuropsychology: Official Journal of the International Neuropsychological Society, 22(4), 518-528.
6. Army Individual Test Battery (1944). Manuel of directions and scoring. Washington, DC: War Department, Adjutant General's Office.
7. Avants, S. K., Margolin, A., Warburton, L. A., Hawkins, K. A., & Shi, J. (2001). Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. The American Journal on Addictions/American Academy of Psychiatrists in Alcoholism and Addictions, 10(1), 69-78.
8. Baldewicz, T. T., Leserman, J., Silva, S. G., Petitto, J. M., Golden, R. N., & Perkins, D. O. et al. (2004). Changes in neuropsychological functioning with progression of HIV-1 infection: Results of an 8-year longitudinal investigation. AIDS and Behavior, 8(3), 345-355.
9. Bondi, M. W., Drake, A. I., & Grant, I. (1998). Verbal learning and memory in alcohol abusers and polysubstance abusers with concurrent alcohol abuse. Journal of the International Neuropsychological Society: JINS, 4(4), 319-328.
10. Bornstein, R. A., Nasrallah, H. A., Para, M. F., Whitacre, C. C., Rosenberger, P., & Fass, R. J. et al. (1992). Neuropsychological performance in asymptomatic HIV infection. The Journal of Neuropsychiatry and Clinical Neurosciences, 4(4), 386-394.
11. Bybee, J. A., & Zigler, E. (1991). Self-image and guilt: A further test of the cognitive-developmental formulation. Journal of Personality, 59(4), 733-745.
12. Carrieri, P., Cailleton, V., Le Moing, V., Spire, B., Dellamonica, P., & Bouvet, E. et al. (2001). The dynamic of adherence to highly active antiretroviral therapy: Results from the french national APROCO cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 28(3), 232-239.
13. Cohen, R. A., Boland, R., Paul, R., Tashima, K. T., Schoenbaum, E. E., & Celentano, D. D. et al. (2001). Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS (London, England), 15(3), 341-345.
14. d'Arminio Monforte, A., Lepri, A. C., Rezza, G., Pezzotti, P., Antinori, A., & Phillips, A. N. et al. (2000). Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. study group. Italian cohort of antiretroviral-naive patients. AIDS (London, England), 14(5), 499-507.
15. Di Stefano, M., Monno, L., Fiore, J. R., Buccoliero, G., Appice, A., & Perulli, L. M. et al. (1998). Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype. AIDS (London, England), 12(7), 737-743.
16. Ellis, R. J., Hsia, K., Spector, S. A., Nelson, J. A., Heaton, R. K., & Wallace, M. R. et al. (1997). Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV neurobehavioral research center group. Annals of Neurology, 42(5), 679-688.
17. Ferrando, S., van Gorp, W., McElhiney, M., Goggin, K., Sewell, M., & Rabkin, J. (1998). Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function. AIDS (London, England), 12(8), F65-F70.
18. Ferrando, S. J., Rabkin, J. G., van Gorp, W., Lin, S. H., & McElhiney, M. (2003). Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection. The Journal of Neuropsychiatry and Clinical Neurosciences, 15(2), 208-214.
19. Gass, C. S., & Daniel, S. K. (1990). Emotional impact on trail making test performance. Psychological Reports, 67(2), 435-438.
20. Gaudino, E. A., Geisler, M. W., & Squires, N. K. (1995). Construct validity in the trail making test: What makes part B harder? Journal of Clinical and Experimental Neuropsychology: Official Journal of the International Neuropsychological Society, 17(4), 529-535.
21. Goodkin, K., Wilkie, F. L., Concha, M., Hinkin, C. H., Symes, S., & Baldewicz, T. T. et al. (2001). Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality. Journal of Clinical Epidemiology, 54(Suppl. 1), S35-S43.
22. Gross, R., Bilker, W. B., Friedman, H. M., & Strom, B. L. (2001). Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS (London, England), 15(16), 2109-2117.
23. Halkitis, P. N., Kutnick, A. H., & Slater, S. (2005). The social realities of adherence to protease inhibitor regimens: Substance use, health care and psychological states. Journal of Health Psychology, 10(4), 545-558.
24. Heaton, R. K., Grant, I., Butters, N., White, D. A., Kirson, D., & Atkinson, J. H. et al. (1995). The HNRC 500-Neuropsychology of HIV infection at different disease stages. HIV neurobehavioral research center. Journal of the International Neuropsychological Society: JINS, 1(3), 231-251.
25. Heaton, R. K., Marcotte, T. D., Mindt, M. R., Sadek, J., Moore, D. J., & Bentley, H. et al. (2004). The impact of HIV-associated neuropsychological impairment on everyday functioning. Journal of the International Neuropsychological Society: JINS, 10(3), 317-331.
26. Hill, Z., Kendall, C., & Fernandez, M. (2003). Patterns of adherence to antiretrovirals: Why adherence has no simple measure. AIDS Patient Care and STDs, 17(10), 519-525.
27. Hinkin, C. H., Castellon, S. A., Durvasula, R. S., Hardy, D. J., Lam, M. N., & Mason, K. I. et al. (2002). Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity. Neurology, 59(12), 1944-1950.
28. Hinkin, C. H., Hardy, D. J., Mason, K. I., Castellon, S. A., Durvasula, R. S., & Lam, M. N. et al. (2004). Medication adherence in HIV-infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS (London, England), 18(Suppl. 1), S19-S25.
29. Hugen, P. W., Langebeek, N., Burger, D. M., Zomer, B., van Leusen, R., & Schuurman, R. et al. (2002). Assessment of adherence to HIV protease inhibitors: Comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. Journal of Acquired Immune Deficiency Syndromes (1999), 30(3), 324-334.
30. Kalichman, S. C., Difonzo, K., Austin, J., Luke, W., & Rompa, D. (2002). Prospective study of emotional reactions to changes in HIV viral load. AIDS Patient Care and STDs, 16(3), 113-120.
31. Kimmerling, M., Wagner, G., & Ghosh-Dastidar, B. (2003). Factors associated with accurate self-reported adherence to HIV antiretrovirals. International Journal of STD and AIDS, 14(4), 281-284.
32. Kortte, K. B., Horner, M. D., & Windham, W. K. (2002). The trail making test, part B: Cognitive flexibility or ability to maintain set? Applied Neuropsychology, 9(2), 106-109.
33. Kruse, W., Rampmaier, J., Ullrich, G., & Weber, E. (1994). Patterns of drug compliance with medication to be taken once and twice daily assessed by continuous electronic monitoring in primary care. International Journal of Clinical Pharmacology Therapy, 32, 453-457.
34. Lezak, M. D. (1995). Neuropsychological assessment (3rd ed.). New York: Oxford University Press.
35. Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., & Sanandaji, S. et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134(10), 968-977.
36. Mannheimer, S., Friedland, G., Matts, J., Child, C., & Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 34(8), 1115-1121.
37. Matsuyama, J. R., Mason, B. J., & Jue, S. G. (1993). Pharmacists' interventions using an electronic medication-event monitoring device's adherence data versus pill counts. The Annals of Pharmacotherapy, 27(7-8), 851-855.
38. McArthur, J. C., McClernon, D. R., Cronin, M. F., Nance-Sproson, T. E., Saah, A. J., & St Clair, M. et al. (1997). Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Annals of Neurology, 42(5), 689-698.
39. Miller, E. N., Selnes, O. A., McArthur, J. C., Satz, P., Becker, J. T., & Cohen, B. A. et al. (1990). Neuropsychological performance in HIV-1-infected homosexual men: The multicenter AIDS cohort study (MACS). Neurology, 40(2), 197-203.
40. Palella, F. J. Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., & Satten, G. A. et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. The New England Journal of Medicine, 338(13), 853-860.
41. Parsons, T. D., Braaten, A. J., Hall, C. D., & Robertson, K. R. (2006). Better quality of life with neuropsychological improvement on HAART. Health and Quality of Life Outcomes [Electronic Resource], 4, 11.
42. Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., & Squier, C. et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1), 21-30.
43. Power, R., Koopman, C., Volk, J., Israelski, D. M., Stone, L., & Chesney, M. A. et al. (2003). Social support, substance use, and denial in relationship to antiretroviral treatment adherence among HIV-infected persons. AIDS Patient Care and STDs, 17(5), 245-252.
44. Rabkin, J. G., & Chesney, M. (1999). Treatment adherence to HIV medications: The Achilles heel of new therapeutics. In D. Ostrow, S. Kalichman (Eds.), New HIV therapies: Psychology and public health implications. New York: Plenum Press.
45. Reger, M., Welsh, R., Razani, J., Martin, D. J., & Boone, K. B. (2002). A meta-analysis of the neuropsychological sequelae of HIV infection. Journal of the International Neuropsychological Society: JINS, 8(3), 410-424.
46. Reitan, R., & Wolfson, D. (1993). The helstead-reitan neuropsychological test battery: Theory and clinical interpretation. Tucson, AZ: Neuropsychological Press.
47. Rosselli, M., & Ardila, A. (1996). Cognitive effects of cocaine and polydrug abuse. Journal of Clinical and Experimental Neuropsychology: Official Journal of the International Neuropsychological Society, 18(1), 122-135.
48. Sankar, A., Golin, C., Simoni, J. M., Luborsky, M., & Pearson, C. (2006). How qualitative methods contribute to understanding combination antiretroviral therapy adherence. Journal of Acquired Immune Deficiency Syndromes (1999), 43(Suppl. 1), S54-S68.
49. Shannon, K., Kerr, T., Lai, C., Ishida, T., Wood, E., & Montaner, J. S. et al. (2005). Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. Journal of the International Association of Physicians in AIDS Care (Chicago, IL: 2002), 4(3), 66-72.
50. Starace, F., Bartoli, L., Aloisi, M. S., Antinori, A., Narciso, P., & Ippolito, G. et al. (2002). Cognitive and affective disorders associated to HIV infection in the HAART era: Findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. the NeuroICONA study. Acta Psychiatrica Scandinavica, 106(1), 20-26.
51. Tombaugh, T. N. (2004). Trail making test A and B: Normative data stratified by age and education. Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists, 19(2), 203-214.
52. Tozzi, V., Balestra, P., Galgani, S., Narciso, P., Sampaolesi, A., & Antinori, A. et al. (2001). Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. Journal of Acquired Immune Deficiency Syndromes (1999), 28(1), 19-27.
53. Tozzi, V., Balestra, P., Murri, R., Galgani, S., Bellagamba, R., & Narciso, P. et al. (2004). Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. International Journal of STD and AIDS, 15(4), 254-259.
54. Treisman, G. J., Angelino, A. F., & Hutton, H. E. (2001). Psychiatric issues in the management of patients with HIV infection. JAMA: The Journal of the American Medical Association, 286(22), 2857-2864.
55. Turner, C. F., Ku, L., Rogers, S. M., Lindberg, L. D., Pleck, J. H., & Sonenstein, F. L. (1998). Adolescent sexual behavior, drug use, and violence: Increased reporting with computer survey technology. Science, 280(5365), 867-873.
56. Valcour, V., & Paul, R. (2006). HIV infection and dementia in older adults. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 42(10), 1449-1454.
57. Wagner, G. J. (2002). Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care and STDs, 16(12), 599-608.
58. Wagner, G. J., & Rabkin, J. G. (2000). Measuring medication adherence: Are missed doses reported more accurately then perfect adherence? AIDS Care, 12(4), 405-408.
59. Wainberg, M. A., & Friedland, G. (1998). Public health implications of antiretroviral therapy and HIV drug resistance. JAMA: The Journal of the American Medical Association, 279(24), 1977-1983.
60. Waterhouse, D. M., Calzone, K. A., Mele, C., & Brenner, D. E. (1993). Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 11(6), 1189-1197.
61. Watters, J. K., & Biernacki, P. (1989). Targeted sampling: Options and considerations for the study of hidden populations. Social Problems, 36, 416-430.